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Abstract
Polymorphic expression of metabolic enzymes have been identified as one of
the key factors responsible for the interindividual/ethnic/racial variability in
drug metabolism and effect. In Nigeria, there is a disproportionately high inci-
dence of sickle-cell disease (SCD), a condition characterized by painful crisis
frequently triggered by malaria. Proguanil, a substrate of the polymorphic
CYP2C19, is a chemoprophylactic antimalarial drug widely used among SCD
patients in Nigeria. This study aimed to conduct a comparative CYP2C19 phe-
notyping among SCD patients and healthy controls and to compare the results
with those previously reported. One hundred seventy-seven unrelated subjects
comprising 131 SCD patients and 46 non-SCD volunteers were phenotyped.
This was carried out by collecting pooled urine samples over 8 h following PG
administration. Proguanil and its major CYP2C19-dependent metabolites were
measured by high-performance liquid chromatography. Metabolic ratios (MRs)
were computed and employed in classifying subjects into poor or extensive
metabolizers. Among SCD group, 130 (99.2%) were extensive metabolizers
(EMs) and 1 (0.8%) was poor metabolizer (PM) of PG, while 95.7 and 4.3%
non-SCDs were EMs and PMs, respectively. MRs ranged from 0.02 to 8.70 for
SCD EMs and from 0.22 to 8.33 for non-SCD EMs. Two non-SCDs with MRs
of 18.18 and 25.76 and the SCD with MR of 16.77 regarded as PMs had earlier
been genotyped as CYP2C19*2/*2. Poor metabolizers of proguanil in SCD
patients are reported for the first time. Regardless of clinical significance, a dif-
ference in metabolic disposition of proguanil and CYP2C19 by SCDs and non-
SCDs was established.
Abbreviations
CG, cycloguanil; CPB, chlorophenylbiguanide; EM, extensive metabolizers; HPLC,
high-performance liquid chromatography; LOD, limit of detection; LOQ, limit of
quantitation; MR, metabolic ratio; PG, proguanil; PLC, performance liquid chro-
matography; PM, poor metabolizer; SCD, sickle-cell disease.
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Introduction
Interindividual, ethnic, and racial variability in drug
metabolism has been largely attributed to polymorphic
expression of metabolizing enzymes, especially cyto-
chrome P450 (CYP) (Mise et al. 2004; Shirasaka et al.
2015). Certain disease conditions, apart from exerting
profound effects on drug metabolism, have been reported
to influence enzyme expressions (Brooks et al. 2007; Mor-
gan 2009; Yeung et al. 2014). Thus, the complex interplay
between genetic, pathologic, and environmental factors
on drug disposition has been the subject of several
research efforts and findings which have impacted thera-
peutic outcomes.
Africa accounts for about 89% of global sickle-cell car-
riers with Nigeria disproportionately contributing over
25% of the global pool. According to a 1989 study, about
2–3% of the Nigerian population have sickle-cell disease
(SCD) (Fleming 1989). Malaria, a mosquito-borne para-
sitic infectious disease, endemic to the tropical regions of
the world, is a frequent precipitating cause of the life-
threatening sickle-cell crises in SCD patients. Thus, the
prophylaxis against malaria has been an important com-
ponent of the prevention of sickle-cell crisis among this
population (Oniyangi and Omari 2006).
Proguanil (PG) is an antimalarial drug widely used in
the tropics for prophylaxis against Plasmodium falciparum
malaria. In Nigeria, it is also the drug of choice for
malaria suppression in patients with SCD (Bolaji et al.
2002). In fact, most SCD patients in Nigeria are placed
on a lifetime antimalarial chemoprophylaxis with progua-
nil (Nwokolo 1960; Bhatt 1994; Oniyangi and Omari
2006). Proguanil exerts its antimalarial effect through the
activity of its active metabolite–cycloguanil (CG) – which
inhibits plasmodial dihydrofolate reductase, impeding
DNA synthesis and cell multiplication in the parasite
(Ward et al. 1991; Fidock et al. 1998).
The metabolism of PG to CG is mediated in the liver pre-
dominantly by CYP2C19, which is known to exhibit genetic
polymorphism, and on the basis of which a population may
be divided into two groups – extensive metabolizers (EMs)
and poor metabolizers (PMs) (Wright et al. 1995; Desta
et al. 2002). CYP2C19 is one of the important CYP in drug
biotransformation, responsible for the primary metabolism
of approximately 10% of commonly used drugs (Gardiner
and Begg 2006), including the proton pump inhibitors, tri-
cyclic antidepressants, some selective serotonin reuptake
inhibitors, benzodiazepines (diazepam, flunitrazepam, qua-
zepam, clobazam), S-mephenytoin, bortezomib, voricona-
zole, selegiline, proguanil, and nelfinavir (Zhou et al. 2009).
Several mutations for the gene that codes for CYP2C19,
and resulting in the production of inactive CYP2C19,
have been identified (De Morais et al. 1994a,b). Specific
base substitution mutations in the gene are responsible
for the PM phenotype which is inherited as a recessive
autosomal trait, while EMs are either heterozygous or
homozygous for the wild-type allele(s) (*1/*2 or *1/*1).
Variability in individual’s response to CYP substrates can,
therefore, be largely attributed to inherited genetic differ-
ences in the drug targets (e.g., receptors and enzymes),
individual’s age, race, organ function, drug interactions,
and concomitant illnesses (Meyer and Zanger 1997;
McLeod and Evans 2001; Evans and McLeod 2003; Wein-
shilboum 2003). Earlier, CYP2D6 polymorphisms has
been reported to exert significant effect of on the response
to pain treatment in pediatric patients experiencing
sickle-cell pain crisis (Brousseau et al. 2007).
The prevalence of PMs varies among races and ranged
from 1% to 7.5% in Black Americans and Black Africans,
3–10% in Caucasians, 19% in Asian populations, and as
high as 70.6% in subjects from Vanuatu (Edstein et al.
1994; Kaneko et al. 1997; Mizutani 2003).
The conversion of S-mephenytoin to its 40-hydroxylated
derivative has been used as a marker for CYP2C19 activity.
The polymorphic expression of CYP2C19 is known to be
responsible for the polymorphism in S-mephenytoin meta-
bolism. Diminished formation of CG from proguanil has
been shown in poor metabolizers of S-mephenytoin, which
demonstrates the dependence of CG formation on
CYP2C19 (Ward et al. 1991; Brøsen et al. 1993). Conse-
quently, urinary recovery of CG has been employed as a
phenotypic probe of CYP2C19 activity assessment (Brøsen
et al. 1993; Wanwimolruk et al. 1995a,b).
Previous studies have reported 4.8% and 4.3% poor
metabolizers of proguanil and S-mephenytoin, respec-
tively, in healthy Nigerian population (Iyun et al. 1990;
Bolaji et al. 2002). With the high SCD burden and
chronic use of proguanil among SCD patients in Nigeria,
this study was aimed at phenotyping SCD patients and
non-SCD controls for CYP2C19 using proguanil metabo-
lism measured through urinary elimination and to com-
pare the results with previously reported genotyping
study in this population.
Materials and Methods
Subjects
This study is a continuation of the study on CYP2C19
genotype earlier reported in Nigerian SCD and healthy
controls (Babalola et al. 2010). For the current study, 193
unrelated Nigerian (143 SCD patients and 50 controls,
aged 6–61 years) volunteers were recruited after written
informed consent was provided. However, phenotype data
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were successfully computed for 177 volunteers (131 SCD
[63 males, 68 females] and 46 healthy controls [21 males,
25 females]). For pediatric subjects, informed consent was
obtained from the parents. SCD patients were recruited
from those attending State Hospital, Ibadan, General
Hospital, Ijebu Ode, General Hospital, Abeokuta and Oni
Memorial Children’s Hospital, Ibadan, all located in the
Southwest of Nigeria. Excluded from the study were indi-
viduals with history of current/recent alcohol consump-
tion and/or tobacco smoking and subjects with
comorbidities and/or on medications including over-the-
counter and herbal drugs. SCD volunteers were only on
routine hematinics specifically folic acid, Vit B Co, Vit C,
and paracetamol; drugs that have not been found to affect
the CYP2C19 phenotype. Control subjects included indi-
viduals with HbAA or HbAS who were healthy as deter-
mined by their medical history and who were not taking
any medications. The study protocol (UI/IRC/05/0067)
was approved by the Joint University of Ibadan/University
College Hospital Institutional Review Committee. Blood
samples (5 mL) were collected from every participant for
hematology screening where RBC count, hematocrit, Hb,
blood group, bilirubin, G6PD status, platelet counts,
reticulocyte counts, HbF and leukocyte counts were deter-
mined and recorded.
Drug administration and sample collection
After emptying their bladder, each subject received pro-
guanil (2.5 mg/kg) based on body weight. Total urine
voided was collected over 8 h (Bolaji et al. 2002). Urine
volume and pH were measured and recorded, and ali-
quots of the urine samples immediately stored at 20°C
until analyzed. Samples were collected by phlebotomists/
health workers assisted by nurses.
Drug analysis
Proguanil, cycloguanil, and 4-chlorophenylbiguanide were
analyzed in urine using slightly modified reversed phase
high-performance liquid chromatography (RP-HPLC)
method earlier developed and applied in our laboratory
(Onyeji et al. 1989; Bolaji et al. 2002; Ebeshi et al. 2005).
HPLC instrumentation and chromatographic
conditions
Chromatography was performed with HPLC System (Agi-
lent technologies 1100 Series) equipped with G1379A
degasser, G1311A quaternary pump, syringe loading injec-
tor with a 20-lL loop size and variable wavelength detec-
tor. Chromatographic separations of the compounds were
achieved on Zorbax SB C18 Column (250 9 4.6 mm,
5 lm) at 25°C, and the absorbance was monitored at
254 nm. The mobile phase consisted of methanol/acetoni-
trile/ammonium acetate in the ratio 40:5:55 and pH was
adjusted to 2.2 with 0.5% 75 mmol/L perchloric acid
(HClO4). The flow rate of themobile phasewas set at 1.0 mL/
min,andpyrimethaminewasusedas internal standard.
The limit of detection determined for proguanil and
CG and 4-chlorophenylbiguanide (4CPB) were 5, 9, and
7.5 ng/mL, respectively, while the limit of quantitation
was 15, 26, and 23 ng/mL for proguanil, CG, and 4CPB
respectively.
Chemicals and reagents for HPLC analysis
Proguanil hydrochloride (CAS No 637-32-1; EC No 211-
283-7), cycloguanil (CAS No 516-21-2), and 4-chlorophe-
nylbiguanide (4CPB; Ref No. UC0705108) were received as
gifts from AstraZeneca, England. Paludrine tablets 100 mg
(proguanil B.P.) LOT CT790 manufactured by Boots Con-
tract Manufacturing, Nottingham, United Kingdom, for
AstraZeneca UK Limited (Macclesfield, Cheshire, United
Kingdom) was donated by Reals Pharmaceuticals PLC,
Nigeria. Pyrimethamine powder (BDH) was a kind dona-
tion from Malaria Research Laboratories, IMRAT, Univer-
sity College Hospital, Ibadan. Ammonium acetate,
perchloric acid 60% w/w, diethylether, orthophosphoric
acid, hydrochloric acid, sodium hydroxide, chloroform, tri-
ethylamine, acetone, HPLC-grade methanol, and acetoni-
trile were obtained from Sigma Aldrich (St Louis, MO).
Data analysis
The total concentration of PG and its metabolites in urine
was calculated, and the metabolic ratio (MR) – the mea-
sure of enzyme activity – was calculated based on PG/CG
ratios. Subjects were classified phenotypically as PM or
EM types based on MR values greater or less than 10,
respectively, as previously established (Ward et al. 1989).
For correlation analysis, nonparametric Spearman’s rank
correlation coefficient was employed to determine the
association between selected variables.
Statistical analysis
Z-test was used to compare mean MRs for EMs within
the controls and SCD groups. Chi-square test was used to
compare PM frequency among controls for both pheno-
type and genotype studies (4.3% vs. 4.7%; v2 = 0.0047,
P > 0.05). P-values for the comparison of MRs between
*1/*1 and *1/*2 for the groups were obtained by SPSS
version 20, 2014. Mean MRs, ranges, and median for each
population were computed using the Microsoft excel
program.
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Results
One hundred seventy-seven (131 SCD patients and 46
healthy controls) human volunteers were administered
with a single-dose proguanil followed by urinary collec-
tion and analysis for parent drug and the major
CYP2C19-dependent metabolites. None of the subjects
who participated in the study reported any adverse effect.
There was complete resolution and separation of the
parent PG and its two major metabolites – CG and
4CPB. The retention times were 10.13, 4.22 and 3.27 min,
respectively, while the internal standard eluted at
8.99 min. The frequency distribution histograms of the
urinary PG/CG ratios (MR) for the SCD patients and the
healthy controls are shown in Figure 1.
Tables 1 and 2 show the percent dose recoveries of PG,
CG, and 4-CPB in healthy controls and SCD patients,
respectively. MRs for the total EM subpopulation within
the SCD patients ranged from 0.02 to 8.7
(mean  SD = 2.04  1.93; median = 1.27). Using an
antimode of 10 as earlier established for the allotment of
MR in Caucasians (Ward et al. 1989), only one (0.8%)
patient out of the 131 SCD volunteers fell into the PM
phenotype group with an MR of 16.77. All the other 130
SCD subjects, constituting 99.2% were EMs of PG.
The MR for the EMs in the control group ranged from
0.22 to 8.33 (mean  SD = 5.46  2.3; median = 5.49).
Forty-four (44) control subjects phenotyped with MR val-
ues <10 EMs of PG, and this corresponds to EM fre-
quency of 95.7%. Only two control subjects (4.3%) were
identified as PMs, each having a PG/CG ratio >10
(MR = 18.18 and 25.76), respectively. Higher mean MRs
were observed for EMs within the control group
(mean  SD = 5.46  2.3; median = 5.49) than in the
SCD group (mean  SD = 2.04  1.93; median = 1.27)
(P < 0.05). In total, only three subjects of the 177 pheno-
typed corresponding to 1.7% were PMs of PG.
The differences in the mean urinary dose recovery of
CG between the PMs and EMs was significant. In the
SCD patients, the PM excreted only about 7% of the
average quantity of CG excreted by the EMs (Table 2).
While for the healthy control group, PMs, on the average,
excreted about 23.1% of the quantity of CG excreted by
the EMs. The correlation of phenotyping result with ear-
lier genotyping result is shown in Table 3.
Discussion
PG metabolism has been used as a probe to phenotype
126 unrelated healthy Nigerian subjects for polymorphic
drug oxidation (Bolaji et al. 2002) in a study that did not
include SCD patients, the predominant users of the drug
for malaria prophylaxis. The therapeutic efficacy of an
antimalarial drug depends on its bioavailability, the sus-
ceptibility of the parasites, and the antimalarial immune
status of the human host (Kaneko et al. 1999). In the case
Metabolic ratio
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Figure 1. Frequency distribution of proguanil metabolic ratios in 131
SCD patients and 46 healthy control subjects.
Table 1. Mean (SD), urinary recoveries of proguanil and its two
metabolites in 8-h urine and the urinary metabolic ratios in the con-
trol group.
Extensive
metabolizers
Poor
metabolizers1
Number of subjects 44 2
Age (years) 25.31  6.48 21, 23
Weight (kg) 57.29  10.36 68, 60.5
Proguanil (% dose) 0.57  0.51 0.73, 0.58
Cycloguanil (% dose) 0.13  0.14 0.04, 0.02
4-Chlorophenylbiguanide
(% dose)
0.05  0.08 0.09, 0.04
Metabolic ratio 5.46  1.3 18.18, 25.76
(PG/CG) (range) (0.22–8.33) (18.18–25.76)
1Values provided in the column are the individual values for the two
subjects (PM1, PM2).
Table 2. Mean (SD), urinary recoveries of proguanil, and its two
metabolites in 8-h urine and the urinary metabolic ratios (MRs) in the
sickle-cell disease group.
Extensive
metabolizers
Poor
metabolizers
Number of subjects 130 1
Age (years) 18.19  8.37 20
Weight (kg) 38.23  13.18 42
Proguanil (% dose) 0.50  0.63 0.64
Cycloguanil (% dose) 0.44  0.73 0.04
4-Chlorophenylbiguanide (% dose) 0.17  0.29 0.05
MR 2.04  1.93 16.77
(PG/CG) (range) (0.02–8.70)
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of proguanil, CYP2C19-dependent metabolism is neces-
sary for activity. Thus, the understanding of the polymor-
phic expression of CYP2C19 in patients who take
proguanil is clinically important. Patients phenotypic
group (PM or EMs) may, therefore, play important role
in determining the dosage regimens of proguanil. This
study is not just the first to phenotype CYP2C19 in Nige-
rian SCD patients in comparison with healthy controls,
and its use of proguanil is important as it reflects applica-
ble clinical situations.
Total 8-h period of pooled urine has earlier been vali-
dated for sufficient proguanil metabolism for useful MR
computation (Bolaji et al. 2002). Pharmacokinetic studies
of proguanil, as available in literature, reported that the
peak concentrations of proguanil and cycloguanil are
achieved within 2–4 and 4–7 h post dose, respectively
(Wattanagoon et al. 1987). This further supports the
appropriateness of 8-h urinary analysis for proguanil and
its metabolites.
From the results, 4.3% of the healthy control subjects
were PMs and this was comparable to 4.8% PMs reported
in a previous study involving healthy subjects (Bolaji
et al. 2002). Table 3 shows the comparisons of the results
from this study with previously reported values from dif-
ferent studies in Nigerian population. From Table 3, it
could be seen that PM phenotype frequencies for healthy
subjects from the different studies were similar, with val-
ues of 4.3% (this study), 4.3% (Iyun et al. 1990), 4.8%
(Bolaji et al. 2002), and 4.7% (Babalola et al. 2010).
These results were also comparable to the values reported
for other Black African populations which ranged from
1.0% to 7.5% (Xie et al. 1999) and 4% in Zimbabweans
(Masimirembwa et al. 1995). The 0.8% PMs in SCD
patients, within the statistical limits, may signify signifi-
cant difference, worthy of further investigation in this
group. Lower number of PMs in SCD patients may
reduce the incidence of subtherapeutic exposure to CG
after proguanil administration. The other possibility is the
increased risk of accumulation of CYP2C19 substrate
drugs in PM phenotype group. This may be important
because the majority of subjects are EMs, a factor that
might have influenced the decision of current dosage
guidelines.
Generally, however, these observations were not signifi-
cantly different (P > 0.05) from what was observed from
the genotyping study in this same population which
reported 99.1% EMs and 0.9% PMs (Babalola et al.
2010). Also, the phenotypic PM frequency for the healthy
controls in this study was not different from the previ-
ously reported genotypic frequency (phenotype vs. geno-
type; 4.3% vs. 4.7%, P > 0.05) (Babalola et al. 2010). This
implies a good correlation between the phenotype fre-
quencies obtained in this study and the previously
reported genotype frequencies. For example, two volun-
teers with MRs of 18.18 and 25.76 among the non-SCD
and one SCD patient with MR of 16.77 were genotyped
as CYP2C19*2/*2. They were also phenotyped as PM
showing complete concordance between genotyping and
phenotyping of CYP2C19. The PM frequency in the total
population phenotyped was 1.7% and 98.3% EMs, and
this also correlated with 1.9% PMs and 98.1% EMs previ-
ously reported from the genotype study (Babalola et al.
2010).
Overall, the results revealed that the frequency of PMs
was lower in SCD patients (phenotype vs. genotype: 0.8%
vs. 0.9%) than in healthy volunteers (phenotype vs. geno-
type: 4.3% vs. 4.7%). This result suggests that SCD
patients who use proguanil daily may have lesser risk of
treatment failure when compared to healthy controls.
However, further studies with more substrates of
CYP2C19 may be required to investigate this.
Furthermore, the lower quantity of CG (Tables 1 and
2) excreted by the PMs may be clinically relevant when
compared to the desired therapeutic range. A previous
report has shown undetectable levels of CG in whole-
blood samples of PMs following proguanil administration
Table 3. Correlation of phenotyping results with reported genotyping in this population and comparison of this study with other studies carried
out in Nigerian subjects.
Phenotyping (current study) Genotyping1 Phenotyping2 Phenotyping3
TP (n) 177 158 126 92
SP (n) SCD (130) Controls (46) SCD (115) Controls (43) Healthy volunteers Healthy volunteers
Extensive metabolizers (%) 130 (99.2) 44 (95.7) 114 (99.1) 41 (95.3) 120 (95.2) 88 (95.7)
PM (%) 1 (0.8) 2 (4.3) 1 (0.9) 2 (4.7) 6 (4.8) 4 (4.3)
TP Ems (%) 130 + 44 = 174 (98.3) 114 + 41 = 155 (98.1) n/a n/a
TP PMs (%) 1 + 2 = 3 (1.7) 1 + 2 = 3 (1.9) n/a n/a
TP, total population; SP, study population; SCD, sickle-cell disease; n/a, not applicable; n, number; PM, poor metabolizer.
1Babalola et al. (2010).
2Bolaji et al. (2002).
3Iyun et al. (1990).
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(Watkins et al. 1990). For therapeutic success in prevent-
ing malaria-induced sickle-cell crisis, it may be important
to tailor proguanil dosage based on the phenotype group
of the patient. The findings from this study suggest that
there may be variation in the occurrence of PM and EM
phenotypes in SCD patients compared with other groups.
Conclusion
The prevalence of PM phenotype frequencies was evalu-
ated in Nigerian SCD patients together with healthy con-
trols for the first time. The phenotypic frequencies
obtained in this study were found to correlate with the
previously reported genotypic frequencies in this same
population. Difference in metabolic disposition of pro-
guanil in SCDs and non-SCDs was observed.
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